An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in ...

The antibody lecanemab is the first authorized therapy in Europe that targets the underlying process of Alzheimer's, rather than only treating symptoms.

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a person’s ...

Leqembi is an infusion therapy approved by the Food and Drug Administration in 2023. It targets and removes the beta-amyloid plaque that builds up in the brain of Alzheimer's patients and causes ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

Within the past few years, the FDA approved two groundbreaking drugs that in trials were shown to reduce brain plaque by 27% ...

32,355 people played the daily Crossword recently. Can you solve it faster than others?32,355 people played the daily ...

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive decline was not large enough to outweigh the risk of serious brain swelling ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible brain swelling and bleeding. Although the drug is alr ...

Leqembi is an infusion therapy approved by the Food and Drug Administration in 2023. It targets and removes the beta-amyloid ...

Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 ...